2012..get set now, page-2

* Patients
* |
* Careers
* |
* Contact Us

*
* About Isis
* Antisense Technology
* Drugs in Development
o Therapeutic Areas
o Current Advances
o Patients
o Partner News
* Investors & Media
* Strategic Alliances

close
To:

From:

Send
Pipeline
Drug Target Partner PreclinicalPhase IPhase IIPhase IIIApprovedhalfandhalf
CARDIOVASCULAR
Mipomersen ApoB-100 Genzyme

ISIS-CRPRx CRP -

ISIS-APOCIIIRx ApoCIII -

ISIS-FXIRx Factor XI -

BMS-PCSK9Rx PCSK9 Bristol-Myers Squibb

ISIS-APOARx Apo(a) -

ISIS-FVIIRx Factor VII -

METABOLIC
ISIS-SGLT2Rx SGLT2 -

ISIS-PTP1BRx PTP-1B -

ISIS-GCGRRx GCGR -

ISIS-GCCRRx GCCR -

ISIS-FGFR4Rx FGFR4 -

ISIS-DGAT2Rx DGAT2 -

CANCER
OGX-011 clusterin Teva/OncoGenex

LY2181308 survivin Lilly

ISIS-EIF4ERx eIF-4E -

OGX-427 Hsp27 OncoGenex

ISIS-STAT3Rx STAT3 -

SEVERE & RARE / NEURODEGENERATIVE
ISIS-SOD1Rx SOD1 ALSA, MDA

ISIS-TTRRx TTR GSK

ISIS-SMNRx SMN2 -

ISIS-AATRx AAT GSK

INFLAMMATION AND OTHER
Vitravene CMV Novartis

Alicaforsen ICAM-1 Atlantic

Plazomicin Aminoglycoside Achaogen

ATL1102 VLA-4 Antisense

EXC 001 CTGF Excaliard

iCo-007 C-raf kinase iCo

ATL1103 GHr Antisense
.......................................................Look above ATL 1102 and 1103 feature in ISIS pipeline...under inflammation and other...